Agonists of MAS oncogene and angiotensin II type 2 receptors attenuate cardiopulmonary disease in rats with neonatal hyperoxia-induced lung injury

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 305, Issue 5, 2013, Pages

  Wagenaar, Gerry T M ^a   Laghmani, El Houari ^a   Fidder, Melissa ^a   Sengers, Rozemarijn M A ^a   de Visser, Yvonne P ^a   de Vries, Louwe ^b   Rink, Rick ^b   Roks, Anton J M ^c   Folkerts, Gert ^d   Walther, Frans J ^a,e  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Lanthio Pharma   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

^e HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Angiotensin (1 7); Bronchopulmonary dysplasia; Lung inflammation; Pulmonary hypertension; Right ventricular hypertrophy

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR TYPE 2 AGONIST; CANG (1-7); DKCANG (1-7); FIBRIN; MESSENGER RNA; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; OXYGEN; RESPIRATORY TRACT AGENT; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL WALL THICKNESS; ARTERIOLE; ARTICLE; BLOOD VESSEL INJURY; CHEMOPROPHYLAXIS; CHRONIC LUNG DISEASE; CONTROLLED STUDY; ENZYME INHIBITION; FIBRIN DEPOSITION; GENE EXPRESSION; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; HYPEROXIA; INFLAMMATION; INFLAMMATORY CELL; LUNG ALVEOLUS; LUNG ALVEOLUS WALL; LUNG DEVELOPMENT; LUNG INJURY; MACROPHAGE; MAS ONCOGENE; NEUTROPHIL; NEWBORN; NEWBORN DISEASE; NONHUMAN; ONCOGENE; PNEUMONIA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANGIOTENSIN-(1-7); BRONCHOPULMONARY DYSPLASIA; LUNG INFLAMMATION; PULMONARY HYPERTENSION; RIGHT VENTRICULAR HYPERTROPHY;

ANGIOTENSIN I; ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; BLOTTING, WESTERN; BRONCHOALVEOLAR LAVAGE; CELL PROLIFERATION; HYPEROXIA; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; LUNG INJURY; MALE; OXYGEN; PEPTIDE FRAGMENTS; PNEUMONIA; PROTO-ONCOGENE PROTEINS; RATS; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, ANGIOTENSIN, TYPE 2; RECEPTORS, G-PROTEIN-COUPLED; RENIN-ANGIOTENSIN SYSTEM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84883331559     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00360.2012     Document Type: Article

References (50)

1. Abman SH. Recent advances in the pathogenesis and treatment of persistent pulmonary hypertension of the newborn. Neonatology 91: 283-290, 2007.
2. Abman SH. Role of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Annu Rev Med 60: 13-23, 2009.
3. Adachi Y, Saito Y, Kishimoto I, Harada M, Kuwahara K, Takahashi N, Kawakami R, Nakanishi M, Nakagawa Y, Tanimoto K, Saitoh Y, Yasuno S, Usami S, Iwai M, Horiuchi M, Nakao K. Angiotensin II type 2 receptor deficiency exacerbates heart failure and reduces survival after acute myocardial infarction in mice. Circulation 107: 2406-2408, 2003.
4. Alenina N, Xu P, Rentzsh B, Patkin EL, Bader M. Genetically altered animal models for MAS and angiotensin-(1-7). Exp Physiol 93: 528-537, 2008.
5. Baraldi E, Filippone M. Chronic lung disease after premature birth. N Engl J Med 357: 1946-1955, 2007.
6. Batenburg WW, Garrelds IM, Bernasconi CC, Juillerat-Jeanneret L, van Kats JP, Saxena PR, Danser AH. Angiotensin II type 2 receptormediated vasodilation in human coronary microarteries. Circulation 109: 2296-2301, 2004.
7. Chou HC, Lang YD, Wang LF, Wu TY, Hsieh YF, Chen CM. Angiotensin II type 1 receptor antagonist attenuates lung fibrosis in hyperoxia-exposed newborn rats. J Pharmacol Exp Ther 340: 169-175, 2012.
8. da Silveira KD, Coelho FM, Vieira AT, Sachs D, Barroso LC, Costa VV, Bretas TL, Bader M, de Sousa LP, da Silva TA, dos Santos RA, Simões e Silva AC, Teixeira MM. Anti-inflammatory effects of the activation of the angiotensin-(1-7) receptor, MAS, in experimental models of arthritis. J Immunol 185: 5569-5576, 2010.
9. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52: 415-472, 2000.
10. de Visser YP, Walther FJ, Laghmani EH, Boersma H, van der Laarse A, Wagenaar GT. Sildenafil attenuates pulmonary inflammation and fibrin deposition, mortality and right ventricular hypertrophy in neonatal hyperoxic lung injury. Respir Res 10: 30, 2009.
11. de Visser YP, Walther FJ, Laghmani EH, van der Laarse A, Wagenaar GT. Apelin attenuates hyperoxic lung and heart injury in neonatal rats. Am J Respir Crit Care Med 182: 1239-1250, 2010.
12. de Visser YP, Walther FJ, Laghmani EH, Steendijk P, Middeldorp M, van der Laarse A, Wagenaar GT. Phosphodiesterase-4 inhibition attenuates persistent heart and lung injury by neonatal hyperoxia in rats. Am J Physiol Lung Cell Mol Physiol 302: L56-L67, 2012.
13. de Vries L, Reitzema-Klein CE, Meter-Arkema A, van Dam A, Rink R, Moll GN, Akanbi MH. Oral and pulmonary delivery of thioetherbridged angiotensin-(1-7). Peptides 31: 893-898, 2010.
14. El-Hashim AZ, Renno WM, Raghupathy R, Abduo HT, Akhtar S, Benter IF. Angiotensin 1-7 inhibits allergic inflammation, via the Mas receptor, through suppression of ERK1/2 and NF-κB dependent pathways. Br J Pharmacol 166: 1964-1976, 2012.
15. Esteban V, Heringer-Walther S, Sterner-Kock A, de Bruin R, van den Engel S, Wang Y, Mezzano S, Egido J, Schultheiss HP, Ruiz-Ortega M, Walther T. Angiotensin-(1-7) and the G protein-coupled receptor Mas are key players in renal inflammation. PLoS One 4: e5406, 2009.
16. Faria-Silva R, Duarte FV, Santos RA. Short-term angiotensin(1-7) receptor MAS stimulation improves endothelial function in normotensive rats. Hypertension 46: 948-952, 2005.
17. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA, Fukamizu A, Hui CC, Hein L, Uhlig S, Slutsky AS, Jiang C, Penninger JM. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436: 112-116, 2005.
18. Janssen W, Pullamsetti SS, Cooke J, Weissmann N, Guenther A, Schermuly RT. The role of dimethylarginine dimethylaminohydrolase (DDAH) in pulmonary fibrosis. J Pathol 229: 242-249, 2013.
19. Jobe AH. The new BPD: an arrest of lung development. Pediatr Res 46: 641-643, 1999.
20. Kim S, Iwao H. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 52: 11-34, 2011.
21. Kluskens LD, Nelemans SA, Rink R, de Vries L, Meter-Arkema A, Wang Y, Walther T, Kuipers A, Moll GN, Haas M. Angiotensin-(1-7) with thioether bridge: an angiotensin-converting enzyme-resistant, potent angiotensin-(1-7) analog. J Pharmacol Exp Ther 328: 849-854, 2009.
22. Koppel R, Han RN, Cox D, Tanswell AK, Rabinovitch M. Alpha 1-antitrypsin protects neonatal rats from pulmonary vascular and parenchymal effects of oxygen toxicity. Pediatr Res 36: 763-770, 1994.
23. Li X, Molina-Molina M, Abdul-Hafez A, Uhal V, Xaubet A, Uhal BD. Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis. Am J Physiol Lung Cell Mol Physiol 295: L178-L185, 2008.
24. Marshall RP, Gohlke P, Chambers RC, Howell DC, Bottoms SE, Unger T, McAnulty RJ, Laurent GJ. Angiotensin II and the fibroproliferative response to acute lung injury. Am J Physiol Lung Cell Mol Physiol 286: L156-L164, 2004.
25. Matsoukas JM, Bigam G, Zhou N, Moore GJ. 1H-NMR studies of [Sar1]angiotensin II conformation by nuclear Overhauser effect spectroscopy in the rotating frame (ROESY): clustering of the aromatic rings in dimethylsulfoxide. Peptides 11: 359-366, 1990.
26. Molina-Molina M, Serrano-Mollar A, Bulbena O, Fernandez-Zabalegui L, Closa D, Marin-Arguedas A, Torrego A, Mullol J, Picado C, Xaubet A. Losartan attenuates bleomycin induced lung fibrosis by increasing prostaglandin E2 synthesis. Thorax 61: 604-610, 2006.
27. Paul-Clark MJ, Gilroy DW, Willis D, Willoughby DA, Tomlinson A. Nitric oxide synthase inhibitors have opposite effects on acute inflammation depending on their route of administration. J Immunol 166: 1169-1177, 2001.
28. Podowski M, Calvi C, Metzger S, Misono K, Poonyagariyagorn H, Lopez-Mercado A, Ku T, Lauer T, McGrath-Morrow S, Berger A, Cheadle C, Tuder R, Dietz HC, Mitzner W, Wise R, Neptune E. Angiotensin receptor blockade attenuates cigarette smoke-induced lung injury and rescues lung architecture in mice. J Clin Invest 122: 229-240, 2012.
29. Rey-Parra GJ, Vadivel A, Coltan L, Hall A, Eaton F, Schuster M, Loibner H, Penninger JM, Kassiri Z, Oudit GY, Thébaud B. Angiotensin converting enzyme 2 abrogates bleomycin-induced lung injury. J Mol Med (Berl) 90: 637-647, 2012.
30. Sampaio WO, Souza dos Santos RA, Faria-Silva R, da Mata Machado LT, Schiffrin EL, Touyz RM. Angiotensin-(1-7) through receptor Mas mediated endothelial nitric oxide synthase activation via Akt-dependent pathways. Hypertension 49: 185-192, 2007.
31. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 100: 8258-8263, 2003.
32. Savergnini SQ, Beiman M, Lautner RQ, de Paula-Carvalho V, Allahdadi K, Pessoa DC, Costa-Fraga FP, Fraga-Silva RA, Cojocaru G, Cohen Y, Bader M, Pinto de Almeida A, Rotman G, Souza dos Santos RA. Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the Mas receptor. Hypertension 56: 1-7, 2010.
33. Shenoy V, Ferreira AJ, Qi Y, Fraga-Silva RA, Díez-Freire C, Dooies A, Jun JY, Sriramula S, Mariappan N, Pourang D, Venugopal CS, Francis J, Reudelhuber T, Santos RA, Patel JM, Raizada MK, Katovich MJ. The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 182: 1065-1072, 2010.
34. Steckelings UM, Widdop RE, Paulis L, Unger T. The angiotensin AT2 receptor in left ventricular hypertrophy. J Hypertens 28, Suppl 1: S50-S55, 2010.
35. Steckelings UM, Larhed M, Hallberg A, Widdop RE, Jones ES, Wallinder C, Namsolleck P, Dahlöf B, Unger T. Non-peptide AT2-receptor agonists. Curr Opin Pharmacol 11: 187-192, 2011.
36. Steinhorn RH. Neonatal pulmonary hypertension. Pediatr Crit Care Med 11: S79-S84, 2010.
37. ter Horst SA, Walther FJ, Poorthuis BJ, Hiemstra PS, Wagenaar GT. Inhaled nitric oxide attenuates pulmonary inflammation and fibrin deposition and prolongs survival in neonatal hyperoxic lung injury. Am J Physiol Lung Cell Mol Physiol 293: L35-L44, 2007.
38. Tesanovic S, Vinh A, Gaspari TA, Casley D, Widdop RE. Vasoprotective and atheroprotective effects of angiotensin (1-7) in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 30: 1606-1613, 2010.
39. Tourneux P, Markham N, Seedorf G, Balasubramaniam V, Abman SH. Inhaled nitric oxide improves lung structure and pulmonary hypertension in a model of bleomycin-induced bronchopulmonary dysplasia in neonatal rats. Am J Physiol Lung Cell Mol Physiol 297: L1103-L1111, 2009.
40. Trask AJ, Ferrario CM. Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments. Cardiovasc Drug Rev 25: 162-174, 2007.
41. Tuder RM, Abman SH, Braun T, Capron F, Stevens T, Thistlethwaite PA, Haworth SG. Development and pathology of pulmonary hypertension. J Am Coll Cardiol 54: S3-S9, 2009.
42. Uhal BD, Li X, Piasecki CC, Molina-Molina M. Angiotensin signalling in pulmonary fibrosis. Int J Biochem Cell Biol 44: 465-468, 2012.
43. Varagic J, Trask AJ, Jessup JA, Chappell MC, Ferrario CM. New angiotensins. J Mol Med 86: 663-671, 2008.
44. Verdonk K, Danser AH, van Esch JH. Angiotensin II type 2 receptor agonists: where should they be applied? Expert Opin Investig Drugs 21: 501-513, 2012.
45. Wagenaar GTM, ter Horst SA, van Gastelen MA, Leijser LM, Mauad T, van der Velden PA, de Heer E, Hiemstra PS, Poorthuis BJ, Walther FJ. Gene expression profile and histopathology of experimental bronchopulmonary dysplasia induced by prolonged oxidative stress. Free Radic Biol Med 36: 782-801, 2004.
46. Walters PE, Gaspari TA, Widdop RE. Angiotensin-(1-7) acts as a vasodepressor agent via angiotensin II type 2 receptors in conscious rats. Hypertension 45: 960-966, 2005.
47. Waseda Y, Yasui M, Nishizawa Y, Inuzuka K, Takato H, Ichikawa Y, Tagami A, Fujimura M, Nakao S. Angiotensin II type 2 receptor antagonist reduces bleomycin-induced pulmonary fibrosis in mice. Respir Res 9: 43, 2008.
48. Wösten-van Asperen RM, Lutter R, Specht PA, van Woensel JB, van der Loos CM, Florquin S, Lachmann B, Bos AP. Ventilator-induced inflammatory response in lipopolysaccharide-exposed rat lung is mediated by angiotensin-converting enzyme. Am J Pathol 176: 2219-2227, 2010.
49. Wösten-van Asperen RM, Lutter R, Specht PA, Moll GN, van Woensel JB, van der Loos CM, van Goor H, Kamilic J, Florquin S, Bos AP. Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE-2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist. J Pathol 225: 618-627, 2011.
50. Yi M, Jankov RP, Belcastro R, Humes D, Copland I, Shek S, Sweezey NB, Post M, Albertine KH, Auten RL, Tanswell AK. Opposing effects of 60% oxygen and neutrophil influx on alveologenesis in the neonatal rat. Am J Respir Crit Care Med 170: 1188-1196, 2004.